BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 6226199)

  • 21. Coronary vascular changes in the progression and regression of hypertensive heart disease.
    Strauer BE; Schwartzkopff B; Motz W; Vogt M
    J Cardiovasc Pharmacol; 1991; 18 Suppl 3():S20-7. PubMed ID: 1720480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of manidipine on cardiac hypertrophy and coronary circulation in DOCA/salt hypertensive rats.
    Takeda K; Nakata T; Kuwabara T; Itoh H; Yamahara Y; Takesako T; Tanabe S; Sasaki S; Asayama J; Nakagawa M
    Blood Press Suppl; 1992; 3():48-52. PubMed ID: 1343289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regression of left ventricular mass in systemic hypertension.
    Georgiou D; Brundage BH
    Clin Cardiol; 1992 Jan; 15(1):5-16. PubMed ID: 1531790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypertensive cardiopathy. Functional evaluation during isometric effort after regression of left ventricular hypertrophy].
    Nogueira JB; Freitas A; Morais C; Silva D; Esteves J; da Costa JN
    Rev Port Cardiol; 1992 Mar; 11(3):229-38. PubMed ID: 1535203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adrenergic activity and myocardial anatomy and function in essential hypertension.
    Muiesan G; Agabiti-Rosei E; Muiesan ML
    J Hypertens Suppl; 1985 Dec; 3(4):S45-50. PubMed ID: 3007705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive drug therapy and regression of left ventricular hypertrophy: a review with a focus on diuretics.
    Moser M; Setaro JF
    Eur Heart J; 1991 Sep; 12(9):1034-9. PubMed ID: 1834464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The multifactorial role of catecholamines in hypertensive cardiac hypertrophy.
    Tarazi RC; Sen S; Saragoca M; Khairallah P
    Eur Heart J; 1982 Apr; 3 Suppl A():103-10. PubMed ID: 6210534
    [No Abstract]   [Full Text] [Related]  

  • 28. Coronary hemodynamics in hypertensive heart disease. Basic concepts, clinical consequences, and experimental analysis of regression of hypertensive microangiopathy.
    Strauer BE
    Am J Med; 1988 Mar; 84(3A):45-54. PubMed ID: 2975465
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [ACE inhibition: mechanisms of cardioprotection in heart hypertrophy].
    Motz W; Strauer BE
    Klin Wochenschr; 1991; 69 Suppl 24():39-43; discussion 43-4. PubMed ID: 1830911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Consequences of reversal of hypertensive cardiac hypertrophy by captopril on left ventricular pumping ability and performance.
    Saragoça MA; Cezaretti ML; Bessa AM; Casarini D; Almeida JB; Amorim MP; Ramos OL
    J Hypertens Suppl; 1987 Dec; 5(5):S403-6. PubMed ID: 2965226
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pump performance after regression of cardiac hypertrophy following treatment of hypertension with isradipine.
    Saragoça MA; de Almeida JB; Amorim MP; Portela J; Cezaretti ML; Ramos OL
    J Hypertens Suppl; 1989 Dec; 7(6):S288-9. PubMed ID: 2534415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of structural alterations in hypertension.
    Agabiti-Rosei E; Muiesan ML; Muiesan G
    Am J Hypertens; 1989 Feb; 2(2 Pt 2):70S-76S. PubMed ID: 2522006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of an angiotensin II receptor antagonist, TCV-116, on cardiac hypertrophy and coronary circulation in spontaneously hypertensive rats.
    Takeda K; Fujita H; Nakamura K; Uchida A; Tanaka M; Itoh H; Nakata T; Sasaki S; Nakagawa M
    Blood Press Suppl; 1994; 5():94-8. PubMed ID: 7889211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of antihypertensive therapy on diastolic dysfunction in left ventricular hypertrophy.
    Betocchi S; Chiariello M
    J Cardiovasc Pharmacol; 1992; 19 Suppl 5():S116-21. PubMed ID: 1381787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regression of left ventricular hypertrophy in hypertension with alpha-adrenergic blockade: physiological basis and therapeutic implications.
    Ram CV
    J Hypertens Suppl; 1989 Dec; 7(6):S98-9. PubMed ID: 2576672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of left ventricular hypertrophy: a desirable therapeutic goal?
    Schmieder RE; Messerli FH
    J Cardiovasc Pharmacol; 1990; 16 Suppl 6():S16-22. PubMed ID: 1707110
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effects of nicardipine on left ventricular hypertrophy of the rat with renovascular arterial hypertension].
    Grellet J; Bonoron-Adèle S; Stuyvers B; Tariosse L; Besse P
    Arch Mal Coeur Vaiss; 1988 Jun; 81 Spec No():45-9. PubMed ID: 2973301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hypertensive heart disease with ACE inhibitors.
    Stumpe KO
    J Cardiovasc Pharmacol; 1987; 10 Suppl 6():S166-71. PubMed ID: 2485024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of coronary circulation in hypertensive heart disease for development and prevention of heart failure.
    Strauer BE
    Am J Cardiol; 1990 Apr; 65(14):34G-41G. PubMed ID: 2138855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beta blockers and left ventricular hypertrophy in hypertension.
    Trimarco B; De Luca N; Cuocolo A; Ricciardelli B; Rosiello G; Lembo G; Volpe M
    Am Heart J; 1987 Oct; 114(4 Pt 2):975-83. PubMed ID: 2889345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.